Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

LUSIGNAN

Showing results (601-610 of 628) with videos related to

Pageof 63
Sort By:
Lancet (London, England)|October 16, 2022
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesUtkarsh Agrawal, Stuart Bedston, Colin McCowan, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
BMJ Open|June 19, 2021
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher riskGail Hayward, Christopher C Butler, Ly-Mee Yu, et al.
Influenza and Other Respiratory Viruses|May 14, 2024
End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great BritainHeather J Whitaker, Naoma Willam, Simon Cottrell, et al.
JMIR Public Health and Surveillance|February 19, 2021
Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021Simon de Lusignan, Jamie Lopez Bernal, Rachel Byford, et al.
Influenza and Other Respiratory Viruses|May 22, 2024
Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United KingdomHeather Whitaker, Beth Findlay, Jana Zitha, et al.
Nature Medicine|June 10, 2021
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in ScotlandC R Simpson, T Shi, E Vasileiou, et al.
Diagnostic and Prognostic Research|February 9, 2021
Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic studyBrian D Nicholson, Gail Hayward, Philip J Turner, et al.
Lancet (London, England)|August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
Lancet (London, England)|December 5, 2017
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UKRoger Williams, Graeme Alexander, Iain Armstrong, et al.
Pageof 63

Showing results (601-610 of 628) with videos related to

Sort By:
Pageof 63
Lancet (London, England)|October 16, 2022
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesUtkarsh Agrawal, Stuart Bedston, Colin McCowan, et al.
The Journal of Infection|August 31, 2024
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomesFd Richard Hobbs, Oghenekome A Gbinigie-Thompson, Milensu Shanyinde, et al.
BMJ Open|June 19, 2021
Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher riskGail Hayward, Christopher C Butler, Ly-Mee Yu, et al.
Influenza and Other Respiratory Viruses|May 14, 2024
End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great BritainHeather J Whitaker, Naoma Willam, Simon Cottrell, et al.
JMIR Public Health and Surveillance|February 19, 2021
Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021Simon de Lusignan, Jamie Lopez Bernal, Rachel Byford, et al.
Influenza and Other Respiratory Viruses|May 22, 2024
Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United KingdomHeather Whitaker, Beth Findlay, Jana Zitha, et al.
Nature Medicine|June 10, 2021
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in ScotlandC R Simpson, T Shi, E Vasileiou, et al.
Diagnostic and Prognostic Research|February 9, 2021
Rapid community point-of-care testing for COVID-19 (RAPTOR-C19): protocol for a platform diagnostic studyBrian D Nicholson, Gail Hayward, Philip J Turner, et al.
Lancet (London, England)|August 13, 2021
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy-Mee Yu, Mona Bafadhel, Jienchi Dorward, et al.
Lancet (London, England)|December 5, 2017
Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UKRoger Williams, Graeme Alexander, Iain Armstrong, et al.
Pageof 63